Antiemetic activity of megestrol acetate in patients receiving chemotherapy
Authors:
- 26 April 2010
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 19 (5) , 667-673
Abstract
Several trials had independently noted that patients receiving megestrol acetate had less nausea and vomiting, but this antiemetic activity of megestrol acetate has not been reported separately in the literature. Our objective was to evaluate the antiemetic ability of megestrol acetate in patients receiving chemotherapy. Patients receiving chemotherapy were randomly assigned to receive either megestrol acetate 320 mg PO or placebo before the first day of chemotherapy, followed on days 1-4 by megestrol acetate 320 mg PO combined with granisetron 3 mg IV and metoclopramide 20 mg IM or only granisetron 3 mg IV combined with metoclopramide 20 mg IM in a crossover manner during two consecutive cycles. Rates of complete protection against both vomiting and moderate-to-severe nausea was the primary end point. One hundred patients were enrolled in the study. The antiemetic regimen containing megestrol acetate was superior in providing complete protection from nausea and vomiting (45% megestrol acetate regimen vs.17% no megestrol acetate regimen). Complete response of acute phase in both antiemetic regimens was different (85% megestrol acetate regimen vs. 72% no megestrol acetate regimen). Complete response of delayed emesis was also different (49% megestrol acetate regimen vs. 18% no megestrol acetate regimen). Adverse events were mostly mild to moderate. There were no serious drug-related adverse events between the two antiemetic regimens. Megestrol acetate was shown to be an effective antiemetic agent. Megestrol acetate might be a new antiemetic option for chemotherapy.Keywords
This publication has 24 references indexed in Scilit:
- Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626Journal of Clinical Oncology, 2008
- Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancerCancer, 2007
- In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancerAnnals of Oncology, 2006
- Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus ConferenceAnnals of Oncology, 2005
- Chemotherapy-induced nausea and vomiting in routine practice: a European perspectiveSupportive Care in Cancer, 2004
- Incidence of chemotherapy‐induced nausea and emesis after modern antiemeticsCancer, 2004
- Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group StudyJournal of Clinical Oncology, 2002
- Effect of postchemotherapy nausea and vomiting on health-related quality of lifeSupportive Care in Cancer, 1997
- Controlled Trial of Megestrol Acetate for the Treatment of Cancer Anorexia and CachexiaJNCI: Journal of the National Cancer Institute, 1990
- ADVANCED BREAST CANCER: RESPONSE TO HIGH DOSE ORAL MEDROXYPROGESTERONE ACETATEAustralian and New Zealand Journal of Medicine, 1984